Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;130(6):1196-1202.
doi: 10.1002/jso.27881. Epub 2024 Sep 10.

Laparoscopic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy, an Update From the International PSOGI Registry

M Duran-Martínez  1 , M Bergillos-Giménez  1 , L Rodríguez-Ortíz  1   2 , A Arjona-Sánchez  1   2 ; Laparoscopic PSOGI Registry
Collaborators, Affiliations

Laparoscopic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy, an Update From the International PSOGI Registry

M Duran-Martínez et al. J Surg Oncol. 2024 Nov.

Abstract

Introduction: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are established treatments for peritoneal surface malignancies, traditionally performed via laparotomy. Recent advancements in laparoscopic approaches (L-CRS + HIPEC) have shown promising results in selected patients.

Methods: The PSOGI registry, established in November 2019, collects data from specialized centers performing L-CRS + HIPEC. Data were collected prospectively and analyzed retrospectively, excluding risk-reducing procedures without peritoneal disease. The learning curve was assessed using a 14-cases cutoff.

Results: Today, 323 patients have been registered, 193 were included finally. Perioperative outcomes improved after 14 cases: Length of hospital stay was 7.78 ± 3.64 days (consolidation) versus 8.8 ± 8.79 days (learning) and major morbidity was 0% (consolidation) versus 5% (learning), (p = n.s.). Estimated blood loss was lower in the consolidation phase. Oncological outcomes also improved: Recurrence rate was 8.7% (consolidation) versus 17.8% (learning). Disease-free survival 5 years, 65% (learning) versus 88% (consolidation) (p = 0.012).

Conclusion: The L-CRS + HIPEC is a safe procedure with non-inferior oncologic outcomes which it is evaluating in an IDEAL setting by an international group. The validation of the learning curve, gives us the knowledge that a mentoring program must be setup to reduce the learning curve impact in oncologic failure.

Keywords: HIPEC; cytoreduction; laparoscopy; peritoneal carcinomatosis.

PubMed Disclaimer

References

    1. A. D. Newton, E. K. Bartlett, and G. C. Karakousis, “Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Review of Factors Contributing to Morbidity and Mortality,” Journal of Gastrointestinal Oncology 7, no. 1 (2016): 99–111.
    1. J. M. Foster, R. Sleightholm, A. Patel, et al., “Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High‐Risk Surgical Oncology Procedures,” JAMA Network Open 2, no. 1 (2019): e186847.
    1. R. C. Auer, D. Sivajohanathan, J. Biagi, J. Conner, E. Kennedy, and T. May, “Indications for Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery: A Systematic Review,” European Journal of Cancer 127 (2020): 76–95.
    1. J. Esquivel, A. Averbach, and T. C. Chua, “Laparoscopic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Patients With Limited Peritoneal Surface Malignancies: Feasibility, Morbidity and Outcome in an Early Experience,” Annals of Surgery 253, no. 4 (2011): 764–768.
    1. A. Arjona‐Sanchez, O. Aziz, G. Passot, et al., “Laparoscopic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Limited Peritoneal Metastasis. The PSOGI International Collaborative Registry,” European Journal of Surgical Oncology 47, no. 6 (2021): 1420–1426.

MeSH terms

LinkOut - more resources